Home

IMPROVING PAIN TREATMENT

Developing innovative biopharmacueticals for patients with neuropathic pain

PAIN

A DISEASE MODYFYING APPROACH

 

 

We are working with a unique family of neurotrophic factors for the treatment of peripheral neuropathic pain.

 

Our lead candidate, HB-086 is in early preclinical development, and targets underserved neuropathic pain indications. The family of neurotrophic factors may prove beneficial in a varity of CNS disorders .

 

 

 

THERAPEUTIC AREAS

NEUROPATHIC PAIN

 

Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system. Triggers include endocrine disorders, viral infections injury or nerve toxins (e.g. chemotherapy).

 

 

NEURODEGENERATIVE DISORDERS

 

Degenerative nerve disorders are a broad spectrum of progressive diseases characterized by motor dysfunction, behavioral and personality changes and cognitive decline.

 

HEARING LOSS

 

Hearing loss may be caused by a number of factors, including: genetics, ageing, exposure to noise, infections, trauma, and certain medications or toxins.

 

BETTER LIVES

 

Currently approved drugs for neuropathic pain provide moderate symptomatic relief for a subset of patients. Their use and dosing levels are limited by side effects.

 

Our focus are

  • Developing novel biopharmaceuticals
  • Treating and preventing neuropathic pain
  • Providing safe and well-tolerated biologics to patients
  • Exploring HB-086 and HB-097 in CNS disorders

 

CONTACT US

c/o Cobis

Ole Maal√łes vej 3,

DK-2200

keap@hobatherapeutics.com

Tel: +45 31101285

Hoba Therapeutics

 

Disease modifying treatments for neuropathic pain